CD274 and neoplasm: However, this approach still cannot address the “on‐target but off‐tumor” binding issue faced by anti‐PD‐L1 antibodies, which may result in severe immune‐related adverse events due to PD‐L1 expression on vascular endothelium, pancreatic islet cells, hepatocytes, and mesenchymal stem cells.[30]